Cited by 51Acute Myeloid Leukemia ResearchCell death mechanisms and regulationFlavonoids in Medical Research

Interleukin-1β maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways

Turzanski, J, Grundy, M, Russell, N H, Pallis, M·2004·Leukemia

Abstract

Blast cell survival in suspension culture is associated with chemoresistance in acute myeloid leukaemia (AML). Autonomous production of IL-1beta by AML blasts is linked with a proliferative response, although its role in survival and hence apoptosis-resistance has not been examined in this disease. Cells that secreted more than 19.7 pg/ml IL-1beta were significantly more resistant to spontaneous apoptosis in 48-h culture than those that produced less than 19.7 pg/ml IL-1beta (P=0.008). Exogenous rhIL-1beta significantly enhanced 48-h survival in 25/29 blast cell samples (P=0.0001). IL-1 receptor ligation is known to activate at least three survival pathways: those mediated by PI-3 kinase, IL-1 receptor-associated kinase (IRAK) and ceramidase. In apoptosis-sensitive AML blasts with a strong survival response to rhIL-1beta, inhibitors of all three pathways down-modulated an IL-1beta-mediated increase in blast survival, but only the inhibition of all three pathways totally eliminated viable blasts. In apoptosis-resistant and apoptosis-sensitive primary AML samples, the three inhibitors all increased apoptosis in vitro after 48 h. Exogenous rhIL-1beta induced the hyperphosphorylation of Bcl-2. It also increased the activation of NF-kappaB in 5/15 blast samples. IL-1beta-mediated survival pathways may be a factor in apoptosis-resistance in primary AML blasts, and may therefore contribute to chemoresistance.

Integrity signals

Registry

Crossref · 10.1038/sj.leu.2403457

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Hematological malignancies that frequently carry TET2 founding mutations, such as MDS and AML, display dependencies on IL-1 signaling.

    “hematological malignancies that frequently carry TET2 founding mutations, such as MDS and AML, display dependencies on IL-1 signaling.53, 54, 55”

Cited by

Sorted by citations

Authors
Turzanski, J., Grundy, M., Russell, N. H., & Pallis, M.
Affiliations
University of Nottingham (GB)
Corresponding author
Pallis, M
Venue
Leukemia
Published
2004-08-12
Volume
18
Issue
10
Pages
1662-1670
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2082826369
Cited by
51
References
0
Citations by year
2026: 1 · 2025: 5 · 2024: 3 · 2023: 1 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 4 · 2016: 4 · 2015: 1 · 2014: 1 · 2013: 1 · 2012: 2
FWCI
0.84
Type
journal article
Language
en
Open access
closed
Locations
  • Leukemia (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Pharmacology › Flavonoids in Medical Research
Keywords
IL-1β, acute myeloid leukemia, apoptosis resistance, chemoresistance, IL-1 signaling, PI3-kinase, IRAK, ceramidase, NF-κB activation
MeSH terms
Amidohydrolases, Cell Division, Enzyme Inhibitors, Humans, Interleukin-1, Phenotype, Phosphorylation, Protein Kinases, Recombinant Proteins, Tumor Cells, Cultured, Neoplastic Stem Cells, Signal Transduction, Leukemia, Myeloid, Acute, NF-kappa B, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Phosphatidylinositol 3-Kinases, Interleukin-1 Receptor-Associated Kinases, Ceramidases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review